Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05113342 · ClinicalTrials.gov registry record · Phase 1
Descartes-25 in Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Cartesian Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT05113342: Clinical Trial Phase 1 study, sponsored by Cartesian Therapeutics.
NCT05113342 is a Phase 1 study that was terminated before completion, run by Cartesian Therapeutics. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05113342, a Phase 1 study, was terminated before completion, sponsored by Cartesian Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.
Primary Outcome
Dose Level at which no more than 20% of the patients treated have shown Dose-Limiting Toxicity.
Interventions
- DRUG Descartes-25
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-11-25 |
| Est. Completion | 2024-11-08 |
| Phase | Phase 1 |
Why NCT05113342 stopped before completion
NCT05113342 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Descartes-25 is the first listed.
NCT05113342 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05113342 about?
NCT05113342 is a clinical study titled "Descartes-25 in Relapsed/Refractory Multiple Myeloma". This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.
What is the current status of trial NCT05113342?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2021-11-25. Estimated completion is 2024-11-08.
What interventions are being tested in trial NCT05113342?
The interventions under investigation include: Descartes-25 (DRUG).
Who is sponsoring clinical trial NCT05113342?
This trial is sponsored by Cartesian Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05113342's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI